

Amy S Ruppert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2209064/publications.pdf>

Version: 2024-02-01

63
papers

2,998
citations

331670

21
h-index

175258

52
g-index

63
all docs

63
docs citations

63
times ranked

4146
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528. | 27.0 | 706 |
| 2 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2015, 1, 80. | 7.1 | 498 |
| 3 | DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2016, 48, 253-264. | 21.4 | 254 |
| 4 | Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood</i> , 2014, 123, 1810-1817. | 1.4 | 246 |
| 5 | Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood</i> , 2014, 123, 1207-1213. | 1.4 | 176 |
| 6 | International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. <i>Blood</i> , 2020, 135, 2041-2048. | 1.4 | 158 |
| 7 | Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. <i>Journal of Clinical Oncology</i> , 2011, 29, 1349-1355. | 1.6 | 124 |
| 8 | Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748. | 5.2 | 123 |
| 9 | Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3626-3637. | 1.6 | 71 |
| 10 | TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2169-2174. | 7.1 | 63 |
| 11 | A single-institution retrospective cohort study of first-line EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. <i>British Journal of Haematology</i> , 2018, 180, 259-266. | 2.5 | 53 |
| 12 | Epigenetic silencing of miR-708 enhances NF- κ B signaling in chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2015, 137, 1352-1361. | 5.1 | 52 |
| 13 | Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2015, 6, 1884-1888. | 1.8 | 49 |
| 14 | Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. <i>Journal of Immunology</i> , 2017, 198, 2500-2512. | 0.8 | 43 |
| 15 | Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4322-4327. | 7.1 | 38 |
| 16 | Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020, 61, 387-396. | 1.3 | 29 |
| 17 | Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639. | 1.4 | 27 |
| 18 | Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study. <i>Blood</i> , 2016, 128, 1215-1215. | 1.4 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 25942-25954. | 1.8 | 23 |
| 20 | Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008777. | 2.6 | 22 |
| 21 | Phase 1b Results of a Phase 1b/2 Study of Obinutuzumab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2016, 128, 639-639. | 1.4 | 22 |
| 22 | Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1. | 0.4 | 19 |
| 23 | Proteomic profiling identifies specific histone species associated with leukemic and cancer cells. <i>Clinical Proteomics</i> , 2015, 12, 22. | 2.1 | 18 |
| 24 | Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. <i>International Journal of Cancer</i> , 2017, 140, 1899-1906. | 5.1 | 15 |
| 25 | Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. <i>Blood</i> , 2021, 138, 523-523. | 1.4 | 14 |
| 26 | Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861. | 7.2 | 12 |
| 27 | Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 9-10. | 1.4 | 12 |
| 28 | A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1025-1029. | 0.8 | 11 |
| 29 | Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1993-2001. | 2.0 | 10 |
| 30 | A Single-Institution Retrospective Cohort Study of Patients Treated with R-EPOCH for Richter's Transformation of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2951-2951. | 1.4 | 10 |
| 31 | Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 28684-28696. | 1.8 | 9 |
| 32 | Jumping translocations, a novel finding in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 200-207. | 2.5 | 8 |
| 33 | Overall success rate of a safe and efficacious drug: Results using six phase 1 designs, each followed by standard phase 2 and 3 designs. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 40-50. | 1.1 | 6 |
| 34 | Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance). <i>Blood</i> , 2018, 132, 146-146. | 1.4 | 6 |
| 35 | Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2015, 126, 3983-3983. | 1.4 | 5 |
| 36 | A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 766-774. | 0.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 968-968. | 1.4 | 4 |
| 38 | Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8042-8042. | 1.6 | 4 |
| 39 | Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1005-1012. | 2.3 | 3 |
| 40 | Comparison of clinical scoring systems in aggressive B-cell lymphomas (BCL): An individual patient-level analysis across international trials (SEAL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7544-7544. | 1.6 | 3 |
| 41 | Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 6338. | 12.8 | 3 |
| 42 | Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. <i>Leukemia</i> , 2022, 36, 2129-2131. | 7.2 | 3 |
| 43 | Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597. | 1.3 | 2 |
| 44 | The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2911-2911. | 1.4 | 2 |
| 45 | A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2953-2953. | 1.4 | 2 |
| 46 | A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features. <i>Blood</i> , 2016, 128, 4388-4388. | 1.4 | 2 |
| 47 | Depth of response and progression free survival in CLL patients on ibrutinib.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7514-7514. | 1.6 | 2 |
| 48 | Second cancer incidence in CLL patients receiving BTK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7511-7511. | 1.6 | 2 |
| 49 | Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3. | 1.4 | 1 |
| 50 | Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 2436-2436. | 1.4 | 1 |
| 51 | Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7528-7528. | 1.6 | 1 |
| 52 | Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 22-23. | 1.4 | 1 |
| 53 | A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 27-30. | 1.4 | 1 |
| 54 | Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2021, 35, 3287-3290. | 7.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Utilization of EBV DNA Copy Number Monitoring in Extranodal NK Lymphoma, Nasal Type in Non Asian Patients. Blood, 2012, 120, 5088-5088. | 1.4 | 0 |
| 56 | The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood, 2012, 120, 3865-3865. | 1.4 | 0 |
| 57 | Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). Blood, 2015, 126, 4328-4328. | 1.4 | 0 |
| 58 | A Retrospective Study of Clinical and Laboratory Characteristics in Patients Diagnosed with Platelet Storage Pool Deficiency. Blood, 2018, 132, 1148-1148. | 1.4 | 0 |
| 59 | Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878. | 1.4 | 0 |
| 60 | Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD). , 2019, 2, 079-082. | | 0 |
| 61 | Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.. Journal of Clinical Oncology, 2020, 38, e20004-e20004. | 1.6 | 0 |
| 62 | Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. Blood, 2021, 138, 1563-1563. | 1.4 | 0 |
| 63 | Strategies to Account for Design Misspecifications in Randomized Controlled Trials. , 2022, 1, . | | 0 |